Related Experiment Video
Updated: Aug 24, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
psiTPTE22-HERV functions as a tumor suppressor by inhibiting PI3K/AKT/mTOR/EIF4E signaling
Fei Xu1, Mengwen Zhang1, Suzhan Zhang1
1Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Cancer Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China.
Abstract:
psiTPTE22-HERV is a human-specific gene with unexplored functions. This study investigated its regulation, molecular mechanism, and clinical significance in gastric cancer. psiTPTE22-HERV expression was consistently down-regulated in primary tumors and cancer cell lines across various cancer types, including gastric cancer, as indicated by TCGA data and quantitative PCR analysis. Its down-regulation in gastric cancer cells is mediated by promoter methylation, confirmed through bisulfite genomic sequencing, with expression restored following demethylation treatment. A progressive reduction in psiTPTE22-HERV expression was observed from normal stomach mucosa to adjacent non-tumor tissues and primary tumors, along with increased methylation. psiTPTE22-HERV inhibited cancer cell viability, clonogenicity, cell cycle progression, migration, and invasion while promoting apoptosis. It also suppressed subcutaneous tumor growth and distant metastasis in mice. Transcriptomic analysis revealed that psiTPTE22-HERV disrupted PI3K/AKT/mTOR signaling. Western blotting confirmed that psiTPTE22-HERV reduced protein levels of PI3K, p-AKT, and mTOR. This led to the down-regulation of EIF4E and EIF4EBP1, oncogenic protein synthesis genes and effectors of mTOR signaling, as well as p-EIF4EBP1(Thr70), which is regulated by mTOR. Notably, psiTPTE22-HERV expression was inversely correlated with EIF4E, EIF4EBP1, and p-EIF4EBP1 (Thr70) in gastric tumors (all P < 0.001). Multivariate analysis revealed that psiTPTE22-HERV expression in primary gastric tumors independently predicted survival (P = 0.027). Kaplan-Meier survival analysis showed that low psiTPTE22-HERV expression was associated with shortened survival in gastric cancer patients (P = 0.0009). Overall, psiTPTE22-HERV plays a tumor-suppressive role by inhibiting the PI3K/AKT/mTOR/EIF4E pathway, and its down-regulation serves as an independent marker for poor prognosis in gastric cancer patients.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
The JAK-STAT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
